| . | All patients (n = 66) . | PT– (n = 26) . | PT+ (n = 40) . | P-value . |
|---|---|---|---|---|
| Male sex | 37 (56.1) | 16 (61.5) | 21 (52.5) | .47 |
| Caucasian | 56/61 (91.8) | 23 (88.5) | 33/35 (94.3) | .64 |
| Age at FSGS diagnosis (years) (n = 57) | 17.6 ± 13.0 | 22.2 ± 15.7 | 14.8 ± 10.2 | .06 |
| FSGS diagnosis at <16 years | 31/57 (54.4) | 10/22 (45.5) | 21/35 (60.0) | .28 |
| Time to ESKD (months) (n = 54) | 55 (36; 84) | 49 (36; 93) | 57 (32; 79) | .94 |
| FSGS immunosuppressive treatment of native kidney | ||||
| Steroids | 37/54 (68.5) | 13/21 (61.9) | 24/33 (72.7) | .40 |
| Steroid-sensitivity on native kidney | 7/34 (20.6) | 3/11 (27.3) | 4/23 (17.4) | .66 |
| Cyclosporine | 22/54 (40.7) | 4/21 (19.0) | 18/33 (54.5) | .01 |
| RTX | 2/54 (3.7) | 0/21 (0.0) | 2/33 (6.1) | .52 |
| Two previous KT | 16 (24.2) | 4 (15.4) | 12 (30.0) | .18 |
| Recurrence of FSGS in the first grafta | 65 (98.5) | 25 (96.2) | 40 (100) | .39 |
| Graft loss due to FSGS recurrence | 46/57 (80.7) | 17/22 (77.3) | 29/35 (82.9) | .68 |
| Graft survival (months) (n = 60) | 50 (18; 100) | 72 (21; 158) | 37 (17; 73) | .08 |
| Recurrence of FSGS in the second graftb | 14/16 (87.5) | 4/4 (100) | 10/12 (83.3) | 1.00 |
| Graft loss due to FSGS recurrence | 11/13 (84.6) | 2/4 (50.0) | 9/9 (100) | .08 |
| Graft survival (months) (n = 14) | 36 (10; 86) | 46 (8; 91) | 36 (14; 86) | .89 |
| Age at KT (years) | 40.2 ± 12.6 | 46.5 ± 13.2 | 36.2 ± 10.5 | .002 |
| Living donor | 9/65 (13.8) | 0 (0.0) | 9/39 (23.1) | .009 |
| Living related donor | 8/9 (88.9) | 8/9 (88.9) | NA | |
| DSA at KT | 26/60 (43.3) | 11/24 (45.8) | 15/36 (41.7) | .75 |
| Induction therapy with anti-thymocyte globulin | 52 (78.8) | 20 (76.9) | 32 (80.0) | .77 |
| Immunosuppressive regimen | ||||
| Cyclosporine | 31 (47.0) | 8 (30.8) | 23 (57.5) | .03 |
| Tacrolimus | 35 (53.0) | 18 (69.2) | 17 (42.5) | |
| MMF | 66 (100) | 26 (100) | 40 (100) | NA |
| Steroids | 66 (100) | 26 (100) | 40 (100) | NA |
| RAAS inhibitor during the first year after KT | 37/50 (74.0) | 17/22 (77.3) | 20/28 (71.4) | .64 |
| . | All patients (n = 66) . | PT– (n = 26) . | PT+ (n = 40) . | P-value . |
|---|---|---|---|---|
| Male sex | 37 (56.1) | 16 (61.5) | 21 (52.5) | .47 |
| Caucasian | 56/61 (91.8) | 23 (88.5) | 33/35 (94.3) | .64 |
| Age at FSGS diagnosis (years) (n = 57) | 17.6 ± 13.0 | 22.2 ± 15.7 | 14.8 ± 10.2 | .06 |
| FSGS diagnosis at <16 years | 31/57 (54.4) | 10/22 (45.5) | 21/35 (60.0) | .28 |
| Time to ESKD (months) (n = 54) | 55 (36; 84) | 49 (36; 93) | 57 (32; 79) | .94 |
| FSGS immunosuppressive treatment of native kidney | ||||
| Steroids | 37/54 (68.5) | 13/21 (61.9) | 24/33 (72.7) | .40 |
| Steroid-sensitivity on native kidney | 7/34 (20.6) | 3/11 (27.3) | 4/23 (17.4) | .66 |
| Cyclosporine | 22/54 (40.7) | 4/21 (19.0) | 18/33 (54.5) | .01 |
| RTX | 2/54 (3.7) | 0/21 (0.0) | 2/33 (6.1) | .52 |
| Two previous KT | 16 (24.2) | 4 (15.4) | 12 (30.0) | .18 |
| Recurrence of FSGS in the first grafta | 65 (98.5) | 25 (96.2) | 40 (100) | .39 |
| Graft loss due to FSGS recurrence | 46/57 (80.7) | 17/22 (77.3) | 29/35 (82.9) | .68 |
| Graft survival (months) (n = 60) | 50 (18; 100) | 72 (21; 158) | 37 (17; 73) | .08 |
| Recurrence of FSGS in the second graftb | 14/16 (87.5) | 4/4 (100) | 10/12 (83.3) | 1.00 |
| Graft loss due to FSGS recurrence | 11/13 (84.6) | 2/4 (50.0) | 9/9 (100) | .08 |
| Graft survival (months) (n = 14) | 36 (10; 86) | 46 (8; 91) | 36 (14; 86) | .89 |
| Age at KT (years) | 40.2 ± 12.6 | 46.5 ± 13.2 | 36.2 ± 10.5 | .002 |
| Living donor | 9/65 (13.8) | 0 (0.0) | 9/39 (23.1) | .009 |
| Living related donor | 8/9 (88.9) | 8/9 (88.9) | NA | |
| DSA at KT | 26/60 (43.3) | 11/24 (45.8) | 15/36 (41.7) | .75 |
| Induction therapy with anti-thymocyte globulin | 52 (78.8) | 20 (76.9) | 32 (80.0) | .77 |
| Immunosuppressive regimen | ||||
| Cyclosporine | 31 (47.0) | 8 (30.8) | 23 (57.5) | .03 |
| Tacrolimus | 35 (53.0) | 18 (69.2) | 17 (42.5) | |
| MMF | 66 (100) | 26 (100) | 40 (100) | NA |
| Steroids | 66 (100) | 26 (100) | 40 (100) | NA |
| RAAS inhibitor during the first year after KT | 37/50 (74.0) | 17/22 (77.3) | 20/28 (71.4) | .64 |
Data are presented as the number of patients (percentages), mean ± standard deviation or median (25th; 75th percentiles). In the first column, ‘n’ is the number of available data when the analyses are not performed on the whole sample (n = 66).
The one patient who did not have FSGS recurrence on his first graft had a recurrence on the second.
The two patients who did not have FSGS recurrence on the second graft had a recurrence on the first one.
MMF: mycophenolate mofetil; NA: not applicable; RAAS: renin–angiotensin–aldosterone system.
| . | All patients (n = 66) . | PT– (n = 26) . | PT+ (n = 40) . | P-value . |
|---|---|---|---|---|
| Male sex | 37 (56.1) | 16 (61.5) | 21 (52.5) | .47 |
| Caucasian | 56/61 (91.8) | 23 (88.5) | 33/35 (94.3) | .64 |
| Age at FSGS diagnosis (years) (n = 57) | 17.6 ± 13.0 | 22.2 ± 15.7 | 14.8 ± 10.2 | .06 |
| FSGS diagnosis at <16 years | 31/57 (54.4) | 10/22 (45.5) | 21/35 (60.0) | .28 |
| Time to ESKD (months) (n = 54) | 55 (36; 84) | 49 (36; 93) | 57 (32; 79) | .94 |
| FSGS immunosuppressive treatment of native kidney | ||||
| Steroids | 37/54 (68.5) | 13/21 (61.9) | 24/33 (72.7) | .40 |
| Steroid-sensitivity on native kidney | 7/34 (20.6) | 3/11 (27.3) | 4/23 (17.4) | .66 |
| Cyclosporine | 22/54 (40.7) | 4/21 (19.0) | 18/33 (54.5) | .01 |
| RTX | 2/54 (3.7) | 0/21 (0.0) | 2/33 (6.1) | .52 |
| Two previous KT | 16 (24.2) | 4 (15.4) | 12 (30.0) | .18 |
| Recurrence of FSGS in the first grafta | 65 (98.5) | 25 (96.2) | 40 (100) | .39 |
| Graft loss due to FSGS recurrence | 46/57 (80.7) | 17/22 (77.3) | 29/35 (82.9) | .68 |
| Graft survival (months) (n = 60) | 50 (18; 100) | 72 (21; 158) | 37 (17; 73) | .08 |
| Recurrence of FSGS in the second graftb | 14/16 (87.5) | 4/4 (100) | 10/12 (83.3) | 1.00 |
| Graft loss due to FSGS recurrence | 11/13 (84.6) | 2/4 (50.0) | 9/9 (100) | .08 |
| Graft survival (months) (n = 14) | 36 (10; 86) | 46 (8; 91) | 36 (14; 86) | .89 |
| Age at KT (years) | 40.2 ± 12.6 | 46.5 ± 13.2 | 36.2 ± 10.5 | .002 |
| Living donor | 9/65 (13.8) | 0 (0.0) | 9/39 (23.1) | .009 |
| Living related donor | 8/9 (88.9) | 8/9 (88.9) | NA | |
| DSA at KT | 26/60 (43.3) | 11/24 (45.8) | 15/36 (41.7) | .75 |
| Induction therapy with anti-thymocyte globulin | 52 (78.8) | 20 (76.9) | 32 (80.0) | .77 |
| Immunosuppressive regimen | ||||
| Cyclosporine | 31 (47.0) | 8 (30.8) | 23 (57.5) | .03 |
| Tacrolimus | 35 (53.0) | 18 (69.2) | 17 (42.5) | |
| MMF | 66 (100) | 26 (100) | 40 (100) | NA |
| Steroids | 66 (100) | 26 (100) | 40 (100) | NA |
| RAAS inhibitor during the first year after KT | 37/50 (74.0) | 17/22 (77.3) | 20/28 (71.4) | .64 |
| . | All patients (n = 66) . | PT– (n = 26) . | PT+ (n = 40) . | P-value . |
|---|---|---|---|---|
| Male sex | 37 (56.1) | 16 (61.5) | 21 (52.5) | .47 |
| Caucasian | 56/61 (91.8) | 23 (88.5) | 33/35 (94.3) | .64 |
| Age at FSGS diagnosis (years) (n = 57) | 17.6 ± 13.0 | 22.2 ± 15.7 | 14.8 ± 10.2 | .06 |
| FSGS diagnosis at <16 years | 31/57 (54.4) | 10/22 (45.5) | 21/35 (60.0) | .28 |
| Time to ESKD (months) (n = 54) | 55 (36; 84) | 49 (36; 93) | 57 (32; 79) | .94 |
| FSGS immunosuppressive treatment of native kidney | ||||
| Steroids | 37/54 (68.5) | 13/21 (61.9) | 24/33 (72.7) | .40 |
| Steroid-sensitivity on native kidney | 7/34 (20.6) | 3/11 (27.3) | 4/23 (17.4) | .66 |
| Cyclosporine | 22/54 (40.7) | 4/21 (19.0) | 18/33 (54.5) | .01 |
| RTX | 2/54 (3.7) | 0/21 (0.0) | 2/33 (6.1) | .52 |
| Two previous KT | 16 (24.2) | 4 (15.4) | 12 (30.0) | .18 |
| Recurrence of FSGS in the first grafta | 65 (98.5) | 25 (96.2) | 40 (100) | .39 |
| Graft loss due to FSGS recurrence | 46/57 (80.7) | 17/22 (77.3) | 29/35 (82.9) | .68 |
| Graft survival (months) (n = 60) | 50 (18; 100) | 72 (21; 158) | 37 (17; 73) | .08 |
| Recurrence of FSGS in the second graftb | 14/16 (87.5) | 4/4 (100) | 10/12 (83.3) | 1.00 |
| Graft loss due to FSGS recurrence | 11/13 (84.6) | 2/4 (50.0) | 9/9 (100) | .08 |
| Graft survival (months) (n = 14) | 36 (10; 86) | 46 (8; 91) | 36 (14; 86) | .89 |
| Age at KT (years) | 40.2 ± 12.6 | 46.5 ± 13.2 | 36.2 ± 10.5 | .002 |
| Living donor | 9/65 (13.8) | 0 (0.0) | 9/39 (23.1) | .009 |
| Living related donor | 8/9 (88.9) | 8/9 (88.9) | NA | |
| DSA at KT | 26/60 (43.3) | 11/24 (45.8) | 15/36 (41.7) | .75 |
| Induction therapy with anti-thymocyte globulin | 52 (78.8) | 20 (76.9) | 32 (80.0) | .77 |
| Immunosuppressive regimen | ||||
| Cyclosporine | 31 (47.0) | 8 (30.8) | 23 (57.5) | .03 |
| Tacrolimus | 35 (53.0) | 18 (69.2) | 17 (42.5) | |
| MMF | 66 (100) | 26 (100) | 40 (100) | NA |
| Steroids | 66 (100) | 26 (100) | 40 (100) | NA |
| RAAS inhibitor during the first year after KT | 37/50 (74.0) | 17/22 (77.3) | 20/28 (71.4) | .64 |
Data are presented as the number of patients (percentages), mean ± standard deviation or median (25th; 75th percentiles). In the first column, ‘n’ is the number of available data when the analyses are not performed on the whole sample (n = 66).
The one patient who did not have FSGS recurrence on his first graft had a recurrence on the second.
The two patients who did not have FSGS recurrence on the second graft had a recurrence on the first one.
MMF: mycophenolate mofetil; NA: not applicable; RAAS: renin–angiotensin–aldosterone system.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
